The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer

References

• Bronte G, Rolfo C, Giovannetti E, et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit Rev Oncol Hematol. 2014;89:300–313.
   PubMed Web of Science ®Google Scholar
• Rolfo C, Passiglia F, Castiglia M, et al. ALK and crizotinib: after the honeymoon what else? Resistance mechanisms and new therapies to overcome it. Transl Lung Cancer Res. 2014;3:250–261.
   PubMedGoogle Scholar
• Passiglia F, Bronte G, Castiglia M, et al. Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls? Expert Opin Biol Ther. 2015;15(11):1553–1566.
   Web of Science ®Google Scholar
• Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311:1998–2006.
   PubMed Web of Science ®Google Scholar
• Sholl LM, Aisner DL, Varella-Garcia M, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thorac Oncol. 2015;10:768–777.
   PubMed Web of Science ®Google Scholar
• Vaishnavi A, Cappelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19:1469–1472.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Davis LE, Vaishnavi A, et al. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov. 2015;5:1049–1057.
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Minturn JE, Ho R, et al. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res. 2009;15:3244–3250.
   PubMed Web of Science ®Google Scholar
• Kaplan DR, Martin-Zanca D, Parada LF. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature. 1991;350:158–160.
   PubMed Web of Science ®Google Scholar
• Klein R, Jing SQ, Nanduri V, et al. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell. 1991;65:189–197.
   PubMed Web of Science ®Google Scholar
• Loeb DM, Stephens RM, Copeland T, et al. A Trk nerve growth factor (NGF) receptor point mutation affecting interaction with phospholipase C-gamma 1 abolishes NGF-promoted peripherin induction but not neurite outgrowth. J Biol Chem. 1994;269:8901–8910.
   PubMed Web of Science ®Google Scholar
• Siniscalco D, Giordano C, Rossi F, et al. Role of neurotrophins in neuropathic pain. Curr Neuropharmacol. 2011;9:523–529.
   PubMed Web of Science ®Google Scholar
• Greco A, Miranda C, Pierotti MA. Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol. 2010;321(1):44–49.
   PubMed Web of Science ®Google Scholar
• Pierotti MA, Vigneri P, Bongarzone I. Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Recent Results Cancer Res. 1998;154:237–247.
   PubMedGoogle Scholar
• Greco A, Miranda C, Pagliardini S, et al. Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes. Genes Chromosomes Cancer. 1997;19(2):112–123.
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014;19(3):235–242.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20(12):1479–1484.
   PubMed Web of Science ®Google Scholar
• Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun. 2014;5:3116.
   PubMed Web of Science ®Google Scholar
• Ardini E, Bosotti R, Borgia AL, et al. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol. 2014;8(8):1495–1507.
   PubMed Web of Science ®Google Scholar
• Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014;46(5):444–450.
   PubMed Web of Science ®Google Scholar
• Stransky N, Cerami E, Schalm S, et al. The landscape of kinase fusions in cancer. Nat Commun. 2014;5:4846.
   PubMed Web of Science ®Google Scholar
• Jones DT, Hutter B, Jäger N, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013;45(8):927–932.
   PubMed Web of Science ®Google Scholar
• Leeman-Neill RJ, Kelly LM, Liu P, et al. ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. Cancer. 2014;120(6):799–807.
   PubMed Web of Science ®Google Scholar
• Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2(5):367–376.
   PubMed Web of Science ®Google Scholar
• Bishop JA, Yonescu R, Batista D, et al. Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma. Hum Pathol. 2013;44(10):1982–1988.
   PubMed Web of Science ®Google Scholar
• Knezevich SR, McFadden DE, Tao W, et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18(2):184–187.
   PubMed Web of Science ®Google Scholar
• Harada T, Yatabe Y, Takeshita M, et al. Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res. 2011;17:2638–2645.
   PubMed Web of Science ®Google Scholar
• Sinkevicius KW, Kriegel C, Bellaria KJ, et al. Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis. Proc Natl Acad Sci U S A. 2014;111:10299–10304.
   PubMed Web of Science ®Google Scholar
• Okamura K, Harada T, Wang S, et al. Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer. Lung Cancer. 2012;78:100–106.
   PubMed Web of Science ®Google Scholar
• Varella-Garcia M, Kako S, Nguyen C, et al. FISHing TRK activation by gene rearrangements in non small cell lung cancer. J Thorac Oncol. 2015;10(9). http://journals.lww.com/jto/toc/2015/09001.
   Google Scholar
• Tatematsu T, Sasaki H, Shimizu S, et al. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro. Mol Clin Oncol. 2014;2:725–730.
   PubMedGoogle Scholar
• Farago AF, Le LP, Zheng Z, et al. Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer. J Thorac Oncol. 2015;10:1670–1674.
   PubMed Web of Science ®Google Scholar
• Arevalo JC, Conde B, Hempstead BL, et al. TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor. Mol Cell Biol. 2000;20:5908–5916.
   PubMed Web of Science ®Google Scholar
• Nanda N, Fennel T, Low JA. Identification of tropomyosin kinase receptor (TRK) mutations in cancer. J Clin Oncol. 2015;33(suppl; abstr 1553).
   PubMed Web of Science ®Google Scholar
• Odate S, Nakamura K, Onishi H, et al. TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma. Lung Cancer. 2013;79:205–214.
   PubMed Web of Science ®Google Scholar
• Odate S, Onishi H, Nakamura K, et al. Tropomyosin-related kinase B inhibitor has potential for tumor regression and relapse prevention in pulmonary large cell neuroendocrine carcinoma. Anticancer Res. 2013;33:3699–3703.
   PubMed Web of Science ®Google Scholar
• Anderson D, Ciomei M, Banfi P, et al. Inhibition of Trk-driven tumors by the pan-Trk inhibitor RXDX-101. Ejc. 2014;50(Supplement 6):101.
   Google Scholar
• Ardini E, Menichincheri M, De Ponti C, et al. Characterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer models. Mol Cancer Ther. 2009;8(12 suppl):abstr A243.
   Google Scholar
• Ardini E, Menichincheri M, Banfi P, et al. The ALK inhibitor NMS-E628 also potentially inhibits ROS1 and induces tumor regression in ROS1-driven models. Washington (DC): AACR; 2013. Philadelphia. Abstract n. 2092
   Google Scholar
• Smeyne RJ, Klein R, Schnapp A, et al. Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature. 1994;368:246–249.
   PubMed Web of Science ®Google Scholar
• Longo FM, Massa SM. Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease. Nat Rev Drug Discov. 2013;12:507–525.
   PubMed Web of Science ®Google Scholar
• De Braud FG, Niger M, Damian S, et al. Alka-372-001: First-in-human, phase I study of entrectinib – an oral pan-trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol. 2015;33 (suppl; abstr 2517).
   PubMed Web of Science ®Google Scholar
• Patel MR, Bauer TM, Liu SV, et al. STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol. 2015;33 (suppl; abstr 2596).
   Web of Science ®Google Scholar
• Burris HA, Brose MS, Shaw AT, et al. A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family. J Clin Oncol. 2015;33 (suppl; abstr TPS2624).
   PubMed Web of Science ®Google Scholar
• TRK inhibitor shows early promise. Cancer Discov. 2016;6(1):OF4.
   Google Scholar
• Collisson EA, Campbell JD, Brooks AN, et al. comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–550.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011–1019.
   PubMed Web of Science ®Google Scholar
• Kim DK, Ahn MJ, Shi Y, et al. Updated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol. 2012;30:abstr 7533.
   Google Scholar
• Raez LE. NTRK Family (TRK1, TRK2 and TRK3) and PTPN11: New Targets in NSCLC Therapy. J Thorac Oncol. 2015;10(9). http://journals.lww.com/jto/toc/2015/09001.
   Google Scholar